Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor, ACY-1215, and bortezomib is synergistic in lymphoma

PURPOSE: Pan-class histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform selective HDAC inhibitors are emerging as potentially more targeted agents. HDAC6 is a class IIb deacetylase that facilitates misfolded protein transport to the aggresome for degradation....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Amengual, Jennifer E., Johannet, Paul, Lombardo, Maximilian, Zullo, Kelly, Hoehn, Daniela, Bhagat, Govind, Scotto, Luigi, Jirau-Serrano, Xavier, Radeski, Dejan, Heinen, Jennifer, Jiang, Hongfeng, Cremers, Serge, Zhang, Yuan, Jones, Simon, O’Connor, Owen A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609274/
https://ncbi.nlm.nih.gov/pubmed/26116270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados